Clinical Trial Update: A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial investigating ticagrelor's mechanism of action in inhibiting juvenile platelet ADP response has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• TICAGRELOR (ticagrelor)

Snippet

Sponsor: CirQuest Labs, LLC | Conditions: Diabetes Mellitus | Phase 4 | Status: WITHDRAWN